Rhaeos’ Post

⭐🛰️OroraTech Announces Successful Series B Funding Round🌍🔥 OroraTech, a wildfire intelligence leader, has closed a €25M Series B funding round, led by Korys, European Circular Bioeconomy Fund (ECBF), and Bayern Kapital. This funding will accelerate OroraTech’s expansion into key markets like North America and the Asia Pacific, while advancing its AI-driven wildfire detection and thermal sensor network. Many of OroraTech’s existing investors, including Bayern Kapital, Edaphon, Ananda Impact Ventures, ConActivity KG, and Findus Venture, recommitted capital showing confidence in its solutions and profitable growth momentum. With #wildfires on the rise, OroraTech’s innovations are set to empower global fire agencies to mitigate destruction faster than ever before. 🔎Learn more: https://lnkd.in/egrxQPsa #SpaceNews #OroraTech #WildfireTech #AI #ClimateCrisis #SpaceTech #WildfirePrevention #ClimateAction #TechForGood #ImpactInvesting #VentureCapital #ClimateTech #ThermalIntelligence Martin Langer, Thomas Grübler, Axel Roenneke, Viktor Gauk, Rupert Amann, Florian Mauracher, Zach Ricklefs, Collin Ratzka, Marina Pott, Frederik Simoens, Karel Van Cleemput, Benjamin Schwiewagner, Dr. Nathalie Weitemeyer, Monika Steger, Stéphane Roussel, Giulia Tegas, Hakan Karan, Nicolas de Crombrugghe, Vincent Vliebergh, Cedric Liekens, Joost Van Laer, Guillaume Hollanders, Alice De Schutter, Anna Zimmermann, Oscar de Giey

Excited to have been part of the #SelectUSA event on March 14, 2024!   Our very own Aurore Marie, Director of Cilcare USA and esteemed member of our Executive Committee, shared insights with startups and biotechs about our thriving presence in Boston and the unique advantages of being a Franco-American company. We emphasized the invaluable learnings we've garnered as a company navigating dual cultures and the enriching benefits of our American cultural immersion.   Curious to learn more? Join us!   #Biotech #USA #HearingLoss"

Tech Due-Diligence: mitigating risk when investing in digital innovations I got to exchange experiences and thoughts about how to better manage innovation and all its stakeholders. I took the opportunity to explain how LEVELS as an efficient and quality oriented digital tech provider and studio can help investors mitigate the investment risk. With experience of developing, building and supporting solutions a natural tech due-diligence provider emerges for a demanding investment community. The investor gets not just a second opinion about the technology of the company they are screening but an actual understanding and higher comprehension of what it takes to bring the venture to success.

🎙️ In this episode of Med Tech Talks, we sit down with Dr Amir Zalcenstein, Managing Director of SYNthesis BioVentures. Amir shares his fascinating journey through venture capital and biotech, highlighting the differences between overseas and the Australian medtech landscapes, and why he loves the ASX. He also discusses SYNthesis’ unique approach to early-stage investment in Australian innovations, and says that there’s opportunities to leverage our nation’s wealth, saying: “There is a disconnect between early-stage science, early-stage financing, venture financing, and the ginormous pool of capital that is the Australian capital markets and powered by superannuation savings… you have this gigantic pool of money and you have great science. For whatever reason, there is no organic connection between them. And so what we are hoping to do is to be the ones who provide that continuity of capital.” If you're passionate about the future of med tech, biotech and venture capital, or want insights on global med tech trends, this episode is a must-listen! https://lnkd.in/gTBkj5my #MedTech #Biotech #VentureCapital #Innovation #MedTechTalks #ASX

💼 EIS Investor Panel: Tips for Attracting Venture Capital in Retinal Innovation During the EURETINA Innovation Spotlight (EIS), venture capital experts shared valuable insights for retina specialists and researchers seeking funding for their innovative ideas. Representatives from SOFINNOVA PARTNERS, BIOGENERATION VENTURES, and MONOGRAPH BIO discussed the evolution of investment in retinal treatments over the past decade and what investors are looking for today. Here are some key takeaways: 💡 Lower-risk innovations are increasingly attractive, such as improving drug delivery and duration. 📈 Excite investors with science—investors are drawn to the full picture, from development potential to market size. 💪 Demonstrate clear advantages—ensure your innovation has an easy-to-prove, significant benefit. 🤝 Choose your partners wisely—investor relationships are partnerships, so align your goals. 🔗 Read the full article on the Euretina Congress Daily website: https://ow.ly/I5Xq50TKsVh #EURETINA24 #RetinaCare #VentureCapital #InvestmentTips #InnovationInOphthalmology #EIS2024

Three experts provide valuable insights into how founders can deal with an apparent paradox: building a competent team for the demanding tasks of a biotech start-up, while at the same time financing the company is becoming increasingly difficult. Many thanks to Helena Strigård for the succinct statements. https://lnkd.in/dzXGuzBz #biotech #constares #HaegerCarlsson

The question of whether or not to work with a CMO is one we have helped many of our clients answer, and it is one that has serious implications for determining a startup's success in scaling their technology. Join John Ellersick P.E. PMP tomorrow as he shares our insights from the field in this webinar collaboration with BioP2P Network! We invite all those who are interested in this topic, including current CMO facility owners and/or those who are considering becoming CMO facility owners/operators. Spread the word! Link below, thanks again to BioP2P Network for the opportunity to share. https://lnkd.in/e7Abag5R #scaleup #climatetech #CMO #bioeconomy

Very insightful panel discussion moderated by Lynn Pieper Lewis of Gilmartin Group LLC with John Boyce of TigerGene LLC and Reetika B. of ARCH Venture Partners. Some main topics covered in the discussion were the need for startups executive teams s To show flexibility and willingness to pivot, the importance of an exit strategy when pitching for funding, and the difference between a “cool science” and a science with a clearly defined market, there’s a big difference. LSX USA Congress LSX - partnering for Life Science eXecutives #biotech #medtech #healthtech #scienceandtechnology #lifescience #biotechnology #drugdevelopment #marketing #networking #webdesign

More interesting thoughts from Darwin Ling in the Bullpen Inning 1.

Karius has secured $100m in Series C funding, with the investment round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, and joined by new investor Seventure Partners and existing investor SoftBank Investment Advisers, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Partners, and others. Bloomberg News' Sarah McBride reports on how the funding allows Karius to address the rising demand from healthcare providers to expand access to the #KariusTest beyond the hospital setting. Additionally, it will facilitate research into the broader health implications of Karius' #mcfDNA technology beyond infectious diseases. #funding #biotech #healthcare https://lnkd.in/eSg_jN6Y